Episode

E115: Benralizumab for EGPA - the MANDARA Study

Podcast: The Evidence Based Rheumatology Podcast
Published: Oct 28, 2024
Duration seconds: 592
Processing state: not_requested
Canonical source: https://msputman.podbean.com/e/e115-benralizumab-for-egpa-the-mandara-study/
Audio: https://mcdn.podbean.com/mf/web/b5tawx2n5j4g2nma/e115.mp3
JSON: /v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e115-benralizumab-for-egpa-the-mandara-study
Markdown: /podcast/the-evidence-based-rheumatology-podcast-1130175/e115-benralizumab-for-egpa-the-mandara-study.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e115-benralizumab-for-egpa-the-mandara-study/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e115-benralizumab-for-egpa-the-mandara-study.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Quick rundown of an important rheumatology RCT this week, discussing the IL-5 inhibitor benralizumab for the treatment of relapsing/refractory EGPA. MANDARA Study: https://www.nejm.org/doi/full/10.1056/NEJMoa2311155